Cidara Therapeutics Stock Investor Sentiment

CDTX Stock  USD 22.75  0.48  2.16%   
Slightly above 56% of all Cidara Therapeutics' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Cidara Therapeutics suggests that some traders are interested. Cidara Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Cidara Therapeutics' earnings reports, geopolitical events, and overall market trends.

Comfort Level 56

 Interested

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Cidara Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Cidara Therapeutics.

Cidara Historical Sentiment

Although Cidara Therapeutics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Cidara, such as negative comments on social media and news outlets, may cause fear in the market and push Cidara Therapeutics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Cidara.
  

Cidara Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Cidara Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Cidara Therapeutics Maximum Pain Price Across May 16th 2025 Option Contracts

Cidara Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Cidara Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Cidara Therapeutics' options.
a day ago at gurufocus.com         
Cidara Therapeutics to Participate in World Health Organization Meeting on H5N1 Influenza ...
Gurufocus Stories at Macroaxis
2 days ago at finance.yahoo.com         
Cidara Therapeutics Announces Two Presentations on CD388 in Influenzaat International Conference on ...
Yahoo News
2 days ago at gurufocus.com         
Cidara Therapeutics Announces Two Presentations on CD388 in Infl
Gurufocus Stories at Macroaxis
3 days ago at gurufocus.com         
Cidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature Microbiology
Gurufocus Stories at Macroaxis
few days ago at thelincolnianonline.com         
Leslie Tari Sells 1,773 Shares of Cidara Therapeutics, Inc. Stock
news
six days ago at news.google.com         
Cidara therapeutics chief scientific officer sells shares worth 38,9 - Investing.com
Google News at Macroaxis
over a week ago at thefly.com         
Cidara Therapeutics initiated with bullish view at Citizens JMP, heres why CDTX
news
over a week ago at thelincolnianonline.com         
Analysts Issue Forecasts for CDTX FY2029 Earnings
news
over a week ago at thelincolnianonline.com         
Disposition of 1773 shares by Les Tari of Cidara Therapeutics at 21.9626 subject to Rule 16b-3
news
over a week ago at news.google.com         
HC Wainwright Issues Positive Forecast for Cidara Therapeutics Stock Price - Defense World
Google News at Macroaxis
over a week ago at thelincolnianonline.com         
Cidara Therapeutics Posts Earnings Results, Misses Expectations By 0.10 EPS
news
over a week ago at news.google.com         
Cidara Therapeutics Advances with Strong Financial Backing - TipRanks
Google News at Macroaxis
over a week ago at gurufocus.com         
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 ...
Gurufocus Stories at Macroaxis
over a week ago at globenewswire.com         
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financia...
Macroaxis News: globenewswire.com
over a week ago at finance.yahoo.com         
Cidara Therapeutics Q4 Earnings Snapshot
Yahoo News
Far too much social signal, news, headlines, and media speculation about Cidara Therapeutics that are available to investors today. That information is available publicly through Cidara media outlets and privately through word of mouth or via Cidara internal channels. However, regardless of the origin, that massive amount of Cidara data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Cidara Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Cidara Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Cidara Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Cidara Therapeutics alpha.

Cidara Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Cidara Therapeutics files to sell 7.04M shares of common stocks by selling shareholders
12/23/2024
2
Acquisition by Les Tari of 150224 shares of Cidara Therapeutics at 10.75 subject to Rule 16b-3
01/03/2025
3
Cidara Therapeutics, Inc. Sees Significant Increase in Short Interest
01/29/2025
4
Cidara Therapeutics Rating Increased to Strong-Buy at Cantor Fitzgerald
02/06/2025
5
Disposition of 18478 shares by Taylor Sandison of Cidara Therapeutics at 0.6849 subject to Rule 16b-3
02/14/2025
6
Cidara Therapeutics, Inc. Given Average Recommendation of Buy by Analysts - MarketBeat
02/19/2025
7
Insider Trading
02/24/2025
8
Acquisition by Karbe Frank of 115000 shares of Cidara Therapeutics at 20.5 subject to Rule 16b-3
02/26/2025
9
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 ...
03/06/2025
10
Cidara Therapeutics Advances with Strong Financial Backing - TipRanks
03/07/2025
11
Disposition of 1773 shares by Les Tari of Cidara Therapeutics at 21.9626 subject to Rule 16b-3
03/11/2025
12
Cidara therapeutics chief scientific officer sells shares worth 38,9 - Investing.com
03/13/2025
13
Cidara Therapeutics Announces Two Presentations on CD388 in Infl
03/18/2025

Additional Tools for Cidara Stock Analysis

When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.